




Life Sciences Financing Summary Europe

June 2015

Leaving behind the February slump, the second quarter of 2015 has started strong in the financing of private European Biotech companies (Therapeutics & Diagnostics), notably with investments coming also from the other side of the Atlantic. These companies raised a total of EUR 178m in April in 5 rounds, reaching the largest average amount per investment in the last 14 months at EUR 36m, more than doubling the next in line, September 2014 at EUR 16m.

While April was marked by private investments, two IPOs took place in March: Nordic Nanovector ASA launching with NOK 500m (EUR 58m) and their most advanced product in Phase II clinical trials, and French OSE Pharma, raising EUR 21m and with their most advanced project in Phase III.

The largest private financing round for European Therapeutics & Diagnostics companies in March and April 2015 was raised in April by Nabriva Therapeutics AG at USD 120m (EUR 111m). Continue reading below to learn more about the financing highlights of March and April 2015 in the European Life Science industry.



Source: BiotechgateBiotechgate.com

*The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amounts and number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.



Selected financing highlights: companies raising funds

April 2015

Nabriva Therapeutics Raises USD 120m (EUR 111m) to Advance New Class of Antibiotic

Vienna/Philadelphia – Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, announced, on the 7th of April 2015, the successful completion of a USD 120m (EUR 111m) series B financing. The financing was led by new US based investors Vivo Capital and OrbiMed, and includes EcoR1 Capital, Boxer Capital of Tavistock Life Sciences and new investment from existing investor HBM. Existing investors Phase4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund also participated in the round. Representatives of Vivo Capital and OrbiMed will be joining the Nabriva Supervisory Board.

The initial tranche of USD 50m (EUR 46m) will enable Nabriva to progress its lead product, lefamulin, into clinical phase 3 studies in community-acquired bacterial pneumonia (CABP) and to continue the development of its product pipeline. (*Source: press release*)

CRISPR Therapeutics Raises USD 64m (EUR 59m) in Series A and B

Basel, Switzerland/Cambridge, Massachusetts – CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, announced, on the 29th of April 2015, the closing of a Series A and Series B financing totaling USD 89m (EUR 82m), including USD 35m (EUR 32) of new funding in the Series A and USD 29m (EUR 27m) in the Series B. The oversubscribed Series A and Series B financings were led by strategic investors, SR One and Celgene Corporation, respectively, and included new investors New Enterprise Associates (NEA) and Abingworth, alongside the Company's founding investor, Versant Ventures. (*Source: press release*)

March 2015

Bill & Melinda Gates Foundation Injects USD 52m (EUR 48m) Into CureVac

Tübingen, Germany. CureVac, a company involved in making vaccines, raised USD 52m (EUR 48m) on the 6th of March 2015 from the Bill & Melinda Gates Foundation. It is the largest ever investment by the foundation in a company, reflecting a new strategy of not just giving grants but supporting and having a stake in businesses.

The investment, part of a USD 76m (EUR 70m) round for CureVac, will allow the construction of a manufacturing plant to make products using the company's technology, which will use mRNA as a template for creating new drugs and vaccines. CureVac is pioneering the use of natural and chemically unmodified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. CureVac's novel technology is the broadest and most advanced mRNA therapeutic platform and allows for rapid, low-cost production of multiple drugs and vaccines. Additionally, CureVac's mRNA vaccines are thermostable, which eliminates the demand for cold-chain storage and infrastructure, a major challenge in the vaccine supply of most developing countries. (*Source: press release*)

Selected financing highlights – investors in March, April 2015

The following investors have made investments into European Life Science companies through March, April 2015:

- Abingworth
- Bill & Melinda Gates Foundation
- Boxer Capital of Tavistock Life Sciences
- Celgene Corporation
- EcoR1 Capital
- GLSV
- HBM
- New Enterprise Associates (NEA)
- Novartis Venture
- OrbiMed
- Phase4 Partners
- SR One
- Versant Ventures
- Vivo Capital
- Wellcome Trust




Quarterly Biotech Equity Financing Breakdown by Lead Product Development Phase (Therapeutics & Diagnostics)

The first quarter of 2015 was dominated by private investments in Biotech companies (Therapeutics and Diagnostics) that had the most advanced project either in preclinical stage or in Phase II studies (42% of investments each), following the trend from the last five quarters.

This trend was only broken in Q3 2014, where companies with their most advanced project in preclinical raised 9% of rounds, while companies with projects in Phase III as the most progressed, raised 27%.

Financing by Lead Product Development Phase



Source: BiotechgateBiotechgate.com

The graph above shows the proportion of financing rounds by most advanced project phase in the therapeutics and diagnostics category per quarter, including only private companies

March, April 2015 financing rounds summary

Source: Biotechgate – www.biotechgate.com

Company Name	Sector	Amount (in Million EUR)	Ownership	Country
Newron Pharmaceuticals S.p.A.	Biotechnology - Therapeutics and Diagnostics	23.6	Public	Italy
CRISPR Therapeutics	Biotechnology - Therapeutics and Diagnostics	59.3	Private / independent	Switzerland
Lunaphore Technologies SA	Biotechnology / R&D Services	1.9	Private / independent	Switzerland
Mymetics S.A.	Biotechnology - Therapeutics and Diagnostics	3.4	Public	Switzerland
OMEICOS Therapeutics	Biotechnology - Therapeutics and Diagnostics	6.2	Private / independent	Germany
uniQure	Biotechnology - Therapeutics and Diagnostics	88.5	Public	Netherlands
Minoryx Therapeutics	Biotechnology - Therapeutics and Diagnostics	0.8	Private / independent	Spain
Asceneuron SA	Biotechnology - Therapeutics and Diagnostics	0.3	Private / independent	Switzerland
WILEX AG	Biotechnology - Therapeutics and Diagnostics	4.2	Public	Germany
Nabriva Therapeutics AG	Biotechnology - Therapeutics and Diagnostics	111.2	Private / independent	Austria
Mint Labs	Medical Technology	0.5	Private / independent	Spain
OSE Pharma	Biotechnology - Therapeutics and Diagnostics	21.0	Public	France
Rigontec GmbH	Biotechnology - Therapeutics and Diagnostics	4.8	Private / independent	Germany
Nordic Nanovector ASA	Biotechnology - Therapeutics and Diagnostics	57.9	Public	Norway
Collectis	Biotechnology - Therapeutics and Diagnostics	210.6	Public	France
Phytire Biotech	Biotechnology - other	0.9	Private / independent	Spain
Alize Pharma	Biotechnology - Therapeutics and Diagnostics	1.8	Private / independent	France
Allergy Therapeutics	Biotechnology - Therapeutics and Diagnostics	27.7	Public	United Kingdom
Medicortex Finland Oy,	Biotechnology - Therapeutics and Diagnostics	0.5	Private / independent	Finland
Mininavident AG	Medical Technology	1.3	Private / independent	Switzerland
Addex Therapeutics	Biotechnology - Therapeutics and Diagnostics	2.6	Public	Switzerland
CureVac GmbH	Biotechnology - Therapeutics and Diagnostics	48.0	Private / independent	Germany
Genenta Science	Biotechnology - Therapeutics and Diagnostics	10.0	Private / independent	Italy

About this summary

The Life Sciences Financing Summary is published on a bi-monthly basis by Venture Valuation and Fit for Health 2.0 and can be downloaded for free either from our newsletter or from the website <http://www.fitforhealth.eu/>

The data used for this summary is taken from Venture Valuation's global Biotech and life science database Biotechgate. Biotechgate is a popular source for life sciences company and licensing deals information. If you are interested in learning more, please do not hesitate to contact us and to apply for a trial.

[Click here to learn more about Biotechgate »](#)

Venture Valuation
Kasernenstrasse 11
8004 Zurich
Switzerland

Phone: +41 (43) 321 86 60
Web: www.venturevaluation.com
Email: info@venturevaluation.com

Copyright © 2015 Venture Valuation VV Ltd. All rights reserved. This report is provided for information purposes only. All information regarding financing rounds, deal summaries and merger and acquisition transactions was obtained from company websites or industry newsletters including Fiercebiotech, OnBioVC, and SECA. The above information can also be accessed on the Biotechgate website. All graphical information was provided via Biotechgate. While the information contained herein has been obtained from sources deemed reliable, Venture Valuation VV Ltd makes no guarantees that it is accurate, complete, timely, or sequential. For more information about Biotech companies, including deal, licensing and financing round details, please visit the Biotechgate website at www.biotechgate.com